Non-SMEs to benefit from greater orphan drug fee relief in EU
This article was originally published in SRA
Executive Summary
Larger companies are to benefit from more fee reductions and exemptions for orphan drug services after the European Medicines Agency broadened its fee reduction policy for sponsors that are not micro, small or medium-sized enterprises (SMEs)1.